138 results
6-K
EX-99.1
CNTG
Centogene NV
2 Apr 24
CENTOGENE Receives Nasdaq Non-Compliance Notice
4:30pm
discovery, development, and commercialization in target and drug screening, clinical development, market access and expansion, as well as offering
6-K
EX-99.1
CNTG
Centogene NV
19 Mar 24
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
6:30am
Exhibit 99.1
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage … ) to diagnose patients with Lysosomal Storage Disorders (LSDs).
Under the renewed agreement, CENTOGENE will continue to provide Takeda with access
6-K
CNTG
Centogene NV
19 Mar 24
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
6:30am
Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders.” A copy of the press
6-K
EX-99.1
CNTG
Centogene NV
29 Feb 24
Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected
5:00pm
drug discovery, development, and commercialization in target and drug screening, clinical development, market access and expansion, as well
6-K
EX-99.1
CNTG
Centogene NV
28 Feb 24
CENTOGENE Explores Strategic Alternatives
6:30am
in target and drug screening, clinical development, market access and expansion, as well as offering CENTOGENE Biodata Licenses and Insight Reports
6-K
EX-99.1
fxr3y5iyyo8najup0js
28 Feb 24
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
6:30am
6-K
EX-99.1
qy9ld
25 Jan 24
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
6:30am
6-K
EX-99.1
9gwdwrkq3366iq
24 Jan 24
CENTOGENE Receives French Research Tax Credit Accreditation
6:30am
6-K
EX-99.1
u9k3ot2j nuvqjamq
23 Jan 24
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
6:36am
6-K
EX-99.1
l7p0ga0
18 Jan 24
CENTOGENE Announces Preliminary Full Year 2023 Revenue
7:02am
6-K
EX-99.1
72uzchydigpa
19 Dec 23
CENTOGENE Announces Voting Results of Extraordinary General Meeting
7:10am
6-K
EX-99.1
ht3 4m0817mrhjwuo
18 Dec 23
CENTOGENE Announces Changes in Supervisory Board
6:41am
6-K
EX-99.1
yrg2gp
13 Dec 23
Current report (foreign)
6:33am
6-K
1qhf kd31l
28 Nov 23
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
6:30am
6-K
EX-99.1
wkabq0jgx24y58b
28 Nov 23
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
6:30am
6-K
EX-99.2
z0oa4pmox0jyt
28 Nov 23
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
6:30am
6-K
EX-99.3
lyd7fq
28 Nov 23
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
6:30am
6-K
EX-99.4
8nc7un
28 Nov 23
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
6:30am
6-K
EX-99.2
94c20yw18a7w
27 Oct 23
Variation Agreement to Joint Venture Agreement
7:28am
6-K
EX-99.4
2p1449zsjzg0i0z59u
27 Oct 23
Variation Agreement to Joint Venture Agreement
7:28am